9/16/2023 0 Comments Solid edge v19 trial versionPatients already enrolled in the trial may complete their course of treatment. The company is discontinuing the Phase 3 trial of its SYK inhibitor, entospletinib, for the treatment of newly diagnosed patients with NPM1-mutated acute myeloid leukemia (AML) and plans to close the trial to further enrollment. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the prioritization of its clinical portfolio to focus on the development of its next generation SYK inhibitor, lanraplenib, and its CDK9 inhibitor, KB-0742. 08, 2022 (GLOBE NEWSWIRE) - Kronos Bio, Inc. 30, 2022, Kronos Bio extends expected cash runway from Q4 2024 into Q2 2025Ĭonference call and webcast scheduled for today at 4:30 p.m. With $270.3 million in cash, cash equivalents and investments as of Sept. Company on track to provide KB-0742 update from ongoing Phase 1/2 clinical trial in Q4
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |